Emphysema Market Outlook Signals Expansion To $6.18 Billion Through 2030

Understanding the Emphysema Market Outlook and Key Factors

The emphysema market is on a steady upward trajectory, reflecting growing awareness and advancements in disease management. With continuous improvements in diagnostics, treatment options, and healthcare infrastructure, this sector is poised for notable expansion through the end of the decade. Let's explore the current market size projections, influential players, emerging trends, and detailed segmentation shaping this field.

The emphysema market size has grown steadily in recent years. It will grow from $4.94 billion in 2025 to $5.17 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to smoking prevalence, air pollution exposure, aging population, respiratory disease awareness, healthcare access expansion.

Download a free sample of the emphysema market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Forecasted Expansion and Market Size of the Emphysema Industry

The emphysema market is predicted to experience consistent growth, reaching a valuation of $6.19 billion by 2030. This represents a compound annual growth rate (CAGR) of 4.6% during the forecast period. The growth is driven by initiatives such as early screening programs, increasing adoption of home-based respiratory care, advancements in diagnostic technologies, a stronger focus on managing chronic illnesses, and stricter environmental health regulations. Additional trends supporting market expansion include the rising prevalence of chronic respiratory diseases, greater emphasis on early COPD diagnosis, the growing use of long-term oxygen therapy, the broadening availability of pulmonary rehabilitation programs, and enhanced efforts toward smoking cessation.

View the full emphysema market report:
https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Prominent Companies Leading the Emphysema Market

Several key players dominate the emphysema market landscape, including Pfizer Inc., Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline PLC, Koninklijke Philips N.V., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Mylan N.V., ResMed Inc., Chiesi Farmaceutici S.p.A., VIDA Diagnostics Inc., Pulmonx Corporation, F Hoffmann-La Roche Ltd, Cipla Limited, Abbott Laboratories, Astellas Pharma Inc., Covis Pharma Group, FindAir Sp z o o, Arrowhead Pharmaceuticals, Regeneron Pharmaceuticals, Zydus Lifesciences, Theravance Biopharma Inc, Pulmatrix Inc, Genentech, Dimerix Ltd, and InMed Pharmaceuticals Inc.

In a notable development in October 2023, US-based biopharmaceutical company Aileron Therapeutics Inc. acquired Lung Therapeutics for an undisclosed sum. This acquisition aims to enhance Aileron's pipeline by gaining access to Lung Therapeutics' clinical-stage treatments, including LTI-03, a novel Caveolin-1-related peptide targeting idiopathic pulmonary fibrosis. Lung Therapeutics specializes in developing therapies for severe lung conditions like emphysema, which currently have limited treatment options.

Innovations Driving Positive Momentum in the Emphysema Market

Leading companies in the emphysema space are heavily investing in medical innovations designed to improve treatment outcomes. Among these innovations are inhaled dual inhibitors targeting phosphodiesterase 3 and phosphodiesterase 4 enzymes, which work synergistically to relax airways and reduce inflammation, thereby enhancing lung function and overall disease management.

For example, in June 2024, Verona Pharma plc, a pharmaceutical firm based in the UK, launched Ohtuvayre (ensifentrine). This medication is the first inhaled dual PDE3 and PDE4 inhibitor approved by the US Food and Drug Administration for maintenance therapy in chronic obstructive pulmonary diseases such as emphysema. Marking the first novel inhaled treatment in more than two decades, Ohtuvayre combines bronchodilator and anti-inflammatory effects and will be distributed via specialty pharmacies.

Detailed Emphysema Market Segmentation Breakdown

The emphysema market is categorized using multiple criteria to provide a comprehensive understanding:

1) By Type:
- Centrilobular
- Panlobular

2) By Treatment Method:
- Medication
- Therapy
- Surgery
- Other Treatments

3) By Diagnostic Approach:
- Imaging Test
- Lung Function Test
- Other Diagnostic Methods

4) By Complications:
- Chest Infections
- Collapsed Lung
- Heart Problems
- Lung Holes
- Other Complications

5) By End-User:
- Hospitals and Clinics
- Surgical Centers
- Other End-Users

Subcategories include:
For Centrilobular type - mild, moderate, and severe cases
For Panlobular type - mild, moderate, and severe cases

This segmentation allows for targeted strategies in treatment development, diagnostics, and patient care tailored to specific emphysema types and severity levels.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.